News | Heart Valve Technology | May 08, 2019

Study Finds TAVR Can Be Considered for Patients in All Surgical Risk Classes

Transcatheter aortic valve replacement, previously studied in higher-risk patients, also shows promise for low-risk surgical patients, according to a clinical trial presented at AATS 99th Annual Meeting

Study Finds TAVR Can Be Considered for Patients in All Surgical Risk Classes

May 8, 2019 — Transcatheter aortic valve replacement (TAVR) has been studied as an alternative to surgical aortic valve replacement in high and intermediate-risk surgical patients for more than five years. A new clinical trial, one of two studies on the topic presented at the American Association for Thoracic Surgery’s 99th Annual Meeting, May 4-7 in Toronto, finds the procedure to be equivalent or potentially preferable to surgical aortic valve replacement (SAVR) for low-risk patients.

The international, multicenter, clinical trial enrolled more than 1,400 patients with severe aortic stenosis at low risk for surgical mortality, as determined by local multidisciplinary heart team assessment. Patients were randomized 1:1 to surgery with an aortic valve of the surgeon’s choice or TAVR with a supra-annular self-expanding valve. Endpoints included death from any cause or disabling stroke at 24 months, as well as quality of life and functional recovery at 30 days. Time from procedure to discharge was also measured.

Periprocedural outcomes for both SAVR and TAVR patient categories were equivalently positive, with strong post-procedure benefits for TAVR patients. Of the patients in the study treated with TAVR, only 1 percent were performed through non-femoral access in the groin.  TAVR patients also had fewer re-hospitalizations. Also, TAVR had improved quality of life metrics at 30 days, as did sternal-sparing SAVR, compared to traditional sternotomy SAVR.

According to lead author Basel Ramlawi, M.D., chairman and cardiothoracic surgeon, Heart & Vascular Center at Valley Health, “Anytime you have an equivalent safety and efficacy for a less invasive procedure, the benefits to patients in terms of recovery are superior. For self-expanding TAVR, outcomes were superior to SAVR for many endpoints. With fairly rapid improvements in TAVR technology, we can expect to continue to see improvements in outcomes for patients as the technology matures.”

For more information: www.aats.org


Related Content

News | Cardiovascular Clinical Studies

June 7, 2023 — The U.S. Food and Drug Administration (FDA) has announced the availability of a draft guidance with ...

Home June 07, 2023
Home
News | Cardiovascular Clinical Studies

April 20, 2023 — Researchers led by Northwestern University and the University of Texas at Austin (UT) have developed ...

Home April 20, 2023
Home
News | Cardiovascular Clinical Studies

April 5, 2023 — Acarix, a leader in acoustic and AI-based cardiac diagnostics, announced the release of a new study ...

Home April 05, 2023
Home
News | Cardiovascular Clinical Studies

March 29, 2023 — Irregular sleep patterns may play a role in the pathophysiologic development of cardiovascular disease ...

Home March 29, 2023
Home
News | Cardiovascular Clinical Studies

March 27, 2023 — Tenax Therapeutics, Inc., a specialty pharmaceutical company focused on identifying, developing and ...

Home March 27, 2023
Home
News | Cardiovascular Clinical Studies

March 24, 2023 — Vaxxinity, Inc., a Cape Canaveral, FL-based company pioneering the development of a new class of ...

Home March 24, 2023
Home
News | Cardiovascular Clinical Studies

March 22, 2023 — Ancora Heart, Inc., a privately-held Santa Clara, CA-based company developing a completely ...

Home March 22, 2023
Home
News | Cardiovascular Clinical Studies

March 21, 2023 — The first platform to combine real-world cardiology data from millions of people in multiple European ...

Home March 21, 2023
Home
News | Cardiovascular Clinical Studies

March 13, 2023 — BioCardia, Inc., developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2023
Home
News | Cardiovascular Clinical Studies

March 8, 2023 — A unique community-based partnership, the African American Heart Study, will be conducted to measure the ...

Home March 08, 2023
Home
Subscribe Now